BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

 
• By Joseph Haas

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

FDA Approved typed words on a vintage typewriter
BioCryst gets FDA approval of first oral prophylaxis for HAE

More from New Products

More from Scrip